$Nanoviricides (NNVC.US)$ NEWS NanoViricides Bolsters Partne...
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wide range of viruses, including COVID-19, RSV, Influenza, and Smallpox. The drug's mechanism of action prevents viruses from escaping, even as they mutate.
NV-387 is available in oral syrup, gummy, and injectable forms, addressing various patient needs. The collaboration with Aagami is expected to enhance NanoViricides' business development and licensing efforts while allowing the company to focus on advancing its clinical trials.
NV-387, designed to mimic host-side virus-binding features, targets a wide range of viruses, including COVID-19, RSV, Influenza, and Smallpox. The drug's mechanism of action prevents viruses from escaping, even as they mutate.
NV-387 is available in oral syrup, gummy, and injectable forms, addressing various patient needs. The collaboration with Aagami is expected to enhance NanoViricides' business development and licensing efforts while allowing the company to focus on advancing its clinical trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
837Followers
62Following
5571Visitors
Follow